A recent study found that an anti-Kell antibody level of eight can be used to reliably identify patients at risk of severe ...

Learn more about rebound hyperbilirubinemia in newborns, including its causes, symptoms and treatment options.

Nipocalimab, an emerging therapeutic agent for hemolytic disease of the fetus and newborn (HDFN), does not appear to affect ...

The FDA approved Johnson & Johnson’s nipocalimab, which is also being studied as a potential treatment in HDFN, in myasthenia ...

A study of 85,176 blood samples uncovered 20 cases of HDFN resulting from ABO incompatibility. A study recently published in Transfusion and Apheresis Science developed a workflow to predict cases of ...